Edwards Sapien 3 granted expanded indication from US FDA

Edwards Sapien heart valves
Edwards Sapien heart valves

Edwards Lifesciences has announced US Food and Drug Administration (FDA) approval to expand use of the Edwards Sapien 3 transcatheter heart valve for the treatment of patients suffering from severe, symptomatic aortic stenosis, who have been determined by a heart team to be at intermediate risk for open-heart surgery. The Sapien 3 valve is the first transcatheter aortic valve implantation (TAVI) therapy to obtain this indication in the USA.

Vinod Thourani, co-director of Emory Heart and Vascular Center’s Structural Heart and Valve Center and professor of cardiothoracic surgery at Emory University School of Medicine (both Atlanta, USA) says, “The clinical outcomes of 1.1% mortality and 1% disabling stroke at 30 days in this intermediate-risk population treated with the Sapien 3 valve are changing the paradigm of how we treat patients with aortic stenosis.”

Thourani is the co-principal investigator of the Sapien 3 valve study.

The Sapien 3 valve intermediate-risk approval wa

s based on data from a cohort of the PARTNER II trial, which studied 2,005 intermediate-risk patients at 51 sites in the USA and Canada. The study demonstrated that patients treated with the Sapien 3 valve experienced clinically significant improvements for the composite primary endpoint of mortality, stroke and moderate or severe aortic regurgitation at one year as compared to those treated with surgery.  The data were presented in April at the American College of Cardiology’s 65th Annual Scientific Session (ACC) and simultaneously published in The Lancet.

The expanded intermediate-risk indication granted by the FDA enables heart teams to treat patients with the Sapien 3 valve who they determine to have a predicted risk of surgical mortality of greater than or equal to 3% at 30 days, based on the Society of Thoracic Surgeons risk score and other clinical co-morbidities unmeasured by the calculator.

The Sapien 3 valve was approved by the FDA in June 2015 for the treatment of patients with severe, symptomatic aortic stenosis who are at high-risk for open heart surgery.